• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inspira and Qarakal Sign Joint Development Agreement for Cryogenic Interconnects in Superconducting Quantum Systems

    4/30/26 8:01:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email

    RA'ANANA, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company") today announced the entry into a Joint Development Agreement (the "Agreement") with Qarakal Quantum Ltd. ("Qarakal Quantum" or "Qarakal"), a full-stack quantum computing company developing superconducting quantum computers. The collaboration brings Inspira's Additively Manufactured Electronics (AME) platform, which operates under the brand name QTREX, into a working superconducting quantum environment to address one of the field's most persistent scaling challenges: high-performance signal connectivity in cryogenic environments.

    The Agreement establishes a structured, multi-phase engineering program to test and evaluate Inspira's technology under quantum-relevant cryogenic conditions. Qarakal Quantum will provide the technical requirements for the program, after which the parties will finalize a joint development plan with agreed success metrics, testing scope, timelines, and resource commitments.

    Under the joint development plan, Inspira will provide Qarakal Quantum with 3D-printed conductive and insulating structures designed to test high-density routing, integrated transitions, embedded shielding concepts, monolithic rigid-flex structures, and more compact interconnect geometries within constrained cryogenic volumes. Qarakal Quantum will test and integrate these structures at milli-Kelvin temperatures in its cryogenic development environment and provide engineering feedback.

    Qarakal's technology reflects a convergence of advanced academic research, intellectual property and hands-on engineering execution. Qarakal focuses on the design and fabrication of superconducting quantum processors, along with the development of novel quantum gates and circuits aimed at addressing complex computational challenges beyond the practical reach of classical systems.

    "This Agreement places Inspira's technology in a real-world quantum development environment, where its performance can be evaluated under relevant cryogenic conditions," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "This is a structured technical collaboration built around to be agreed upon defined metrics, direct cryogenic testing, and engineering feedback. This is how real value is built in quantum infrastructure- through measurable execution against one of the field's most important scaling challenges."

    Dr. Nissan Maskil, Chief Executive Officer of Qarakal Quantum, added: "At Qarakal, our mission is to move quantum computing beyond monolithic lab machines toward modular, deployable, and scalable quantum infrastructure. A critical bottleneck in this evolution is the cabling density and thermal efficiency required to manage scaling signal connectivity within the dilution refrigerator."

    This collaboration marks a concrete step in Inspira's strategic expansion into quantum computing and reinforces the Company's focus on addressing one of the field's most important infrastructure bottlenecks: high-performance connectivity within cryogenic environments for superconducting systems.

    About Inspira Technologies

    Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) is a technology company focused on solving the most critical physical and hardware bottlenecks in quantum computing connectivity. Inspira develops unique quantum connectivity solutions designed for high-density, thermally optimized operation in dilution cryostats, a prerequisite for scaling quantum systems beyond current physical limitations. Additionally, the Company continues to advance its medical technology portfolio, including its respiratory support and blood monitoring platforms under a dedicated business unit. For more information, please visit: www.q-trex.com and www.inspira-technologies.com

    About Qarakal Quantum

    Qarakal Quantum is a quantum computing company building modular, deployable superconducting quantum systems designed for real-world scale. By combining application-specific quantum chips, full-stack co-design, and a patented modular architecture, Qarakal enables quantum computers that can be upgraded, expanded, and adapted for operational use—moving the industry beyond monolithic lab machines toward scalable quantum infrastructure. The company was co-founded by its CEO, Dr. Nissan Maskil, who brings deep systems engineering and defense-industry leadership experience, and its CTO, Prof. Nadav Katz of the Hebrew University of Jerusalem, a leading physicist in superconducting quantum systems. For further information, please visit: https://qarakal.ai/

    Forward-Looking Statement Disclaimer

    This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected outcomes and benefits of the Agreement with Qarakal Quantum, including the ability to successfully develop, test and evaluate its cryogenic interconnect technologies under quantum-relevant conditions, , the potential performance and scalability of its solutions in cryogenic environments, the expected value of engineering feedback and performance data obtained through the collaboration, the ability of the Company's technology to address key connectivity challenges in quantum computing infrastructure, the Company's strategic expansion to quantum computing,  Qarakal's mission to move quantum computing beyond monolithic lab machines toward modular, deployable, and scalable quantum infrastructure and the potential for such collaborations to support the Company's broader strategic expansion into the quantum computing market and development of future commercial opportunities. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

    Company Contact

    Inspira Technologies

    Email: info@inspirao2.com

    Phone: +972-9-9664485

    Investor Relations Contact

    Arx Investor Relations

    North American Equities Desk

    inspira@arxhq.com



    Primary Logo

    Get the next $IINN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    SEC Filings

    View All

    SEC Form F-3 filed by Inspira Technologies Oxy B.H.N. Ltd.

    F-3 - QTREX Quantum Ltd. (0001837493) (Filer)

    6/4/26 4:01:49 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - QTREX Quantum Ltd. (0001837493) (Filer)

    6/1/26 4:10:07 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - QTREX Quantum Ltd. (0001837493) (Filer)

    6/1/26 4:01:20 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

    11/1/21 12:39:26 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

    8/26/21 10:05:11 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Yechezkely Hayon Daniella sold $150,000 worth of Ordinary Shares (50,000 units at $3.00), decreasing direct ownership by 6% to 780,000 units (SEC Form 4)

    4 - QTREX Quantum Ltd. (0001837493) (Issuer)

    6/2/26 4:01:56 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Tehila Yafit sold $105,019 worth of Ordinary Shares (30,000 units at $3.50) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 870,000 units (SEC Form 4)

    4 - QTREX Quantum Ltd. (0001837493) (Issuer)

    6/2/26 4:01:35 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    COO and VP of R&D Shabtay Abraham exercised 95,239 units of Ordinary Shares at a strike of $3.37, increasing direct ownership by 8% to 1,332,713 units (SEC Form 4)

    4 - QTREX Quantum Ltd. (0001837493) (Issuer)

    6/2/26 4:01:14 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston

    Nes Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that Mr. Tal Parnas, Chairman of the Company's Board of Directors, and Mr. Yoav Rozanovich, the Company's Chief Business Officer, will be in Boston, Massachusetts during Quantum.Tech World 2026 on June 25–26, 2026, to present functional AME-based monolithic connectivity components engineered for quantum computing systems. QTREX will conduct private, invitation-only meetings with industry leaders, research institutions and strategic partners in a dedic

    6/2/26 7:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials

    Nes Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that it received a purchase order from a Fortune 500 multinational company for an AME system and related materials. The customer is headquartered in the United States, and the AME system will be delivered to one of the customer's sites outside the United States. QTREX's AME system is designed to provide the customer a unique capability that cannot be achieved through conventional technologies: the ability to create intricate structures with advanced m

    6/1/26 9:20:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    QTREX Announces Pricing of a $10 Million Private Placement of Ordinary Shares with a New Fundamental Institutional Investor

    Nes Ziona, Israel, May 29, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a developer of additively manufactured electronics ("AME") technologies for cryogenic interconnect and quantum hardware infrastructure, today announced that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 6,666,667 ordinary shares (or ordinary share equivalents in lieu thereof) in a private placement. The gross proceeds from the offering are expected to be approximately $10 million, before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to

    5/29/26 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Financials

    Live finance-specific insights

    View All

    Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension

    The transaction includes intellectual property, customer-related assets and commercial operations, positioning the Company for the next stage of its strategy Further strategic update to follow shortly RA'ANANA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), today announced the acquisition of Nano Dimension Ltd.'s (NASDAQ:NNDM) ("Nano Dimension") AME platform. The acquired platform includes intellectual property, proprietary high-precision 3D electronic printing systems, patented software, engineering know-how, manufacturing equipment, inventory, customer-related assets, and fully equipped facilities, includin

    4/6/26 8:31:00 AM ET
    $IINN
    $NNDM
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

    RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning

    1/8/26 8:50:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/14/24 3:40:01 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/12/24 4:05:09 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    View All

    Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion

    RA'ANANA, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company") today announced the appointment of Mr. Yoav Rozanovich as Chief Business Officer ("CBO") of Inspira Technologies, reinforcing its commercial execution capabilities following its expansion into quantum computing connectivity and the acquisition of the Additive Manufacturing of Electronics ("AME") business from Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension"). Proven Commercial LeadershipMr. Rozanovich brings international experience across additive manufacturing, advanced electronics, and complex systems integration. From November 2021

    4/14/26 8:01:00 AM ET
    $IINN
    $NNDM
    $SSYS
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 3:40:00 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 9:05:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care